Design and validation of a dosimetric comparison scheme tailored for ultra-high dose-rate electron beams to support multicenter FLASH preclinical studies.

Dosimetry FLASH Intercomparison Passive dosimeters UHDR

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
10 2022
Historique:
received: 29 03 2022
revised: 18 08 2022
accepted: 19 08 2022
pubmed: 29 8 2022
medline: 21 10 2022
entrez: 28 8 2022
Statut: ppublish

Résumé

We describe a multicenter cross validation of ultra-high dose rate (UHDR) (>= 40 Gy/s) irradiation in order to bring a dosimetric consensus in absorbed dose to water. UHDR refers to dose rates over 100-1000 times those of conventional clinical beams. UHDR irradiations have been a topic of intense investigation as they have been reported to induce the FLASH effect in which normal tissues exhibit reduced toxicity relative to conventional dose rates. The need to establish optimal beam parameters capable of achieving the in vivo FLASH effect has become paramount. It is therefore necessary to validate and replicate dosimetry across multiple sites conducting UHDR studies with distinct beam configurations and experimental set-ups. Using a custom cuboid phantom with a cylindrical cavity (5 mm diameter by 10.4 mm length) designed to contain three type of dosimeters (thermoluminescent dosimeters (TLDs), alanine pellets, and Gafchromic films), irradiations were conducted at expected doses of 7.5 to 16 Gy delivered at UHDR or conventional dose rates using various electron beams at the Radiation Oncology Departments of the CHUV in Lausanne, Switzerland and Stanford University, CA. Data obtained between replicate experiments for all dosimeters were in excellent agreement (±3%). In general, films and TLDs were in closer agreement with each other, while alanine provided the closest match between the expected and measured dose, with certain caveats related to absolute reference dose. In conclusion, successful cross-validation of different electron beams operating under different energies and configurations lays the foundation for establishing dosimetric consensus for UHDR irradiation studies, and, if widely implemented, decrease uncertainty between different sites investigating the mechanistic basis of the FLASH effect.

Sections du résumé

BACKGROUND AND PURPOSE
We describe a multicenter cross validation of ultra-high dose rate (UHDR) (>= 40 Gy/s) irradiation in order to bring a dosimetric consensus in absorbed dose to water. UHDR refers to dose rates over 100-1000 times those of conventional clinical beams. UHDR irradiations have been a topic of intense investigation as they have been reported to induce the FLASH effect in which normal tissues exhibit reduced toxicity relative to conventional dose rates. The need to establish optimal beam parameters capable of achieving the in vivo FLASH effect has become paramount. It is therefore necessary to validate and replicate dosimetry across multiple sites conducting UHDR studies with distinct beam configurations and experimental set-ups.
MATERIALS AND METHODS
Using a custom cuboid phantom with a cylindrical cavity (5 mm diameter by 10.4 mm length) designed to contain three type of dosimeters (thermoluminescent dosimeters (TLDs), alanine pellets, and Gafchromic films), irradiations were conducted at expected doses of 7.5 to 16 Gy delivered at UHDR or conventional dose rates using various electron beams at the Radiation Oncology Departments of the CHUV in Lausanne, Switzerland and Stanford University, CA.
RESULTS
Data obtained between replicate experiments for all dosimeters were in excellent agreement (±3%). In general, films and TLDs were in closer agreement with each other, while alanine provided the closest match between the expected and measured dose, with certain caveats related to absolute reference dose.
CONCLUSION
In conclusion, successful cross-validation of different electron beams operating under different energies and configurations lays the foundation for establishing dosimetric consensus for UHDR irradiation studies, and, if widely implemented, decrease uncertainty between different sites investigating the mechanistic basis of the FLASH effect.

Identifiants

pubmed: 36030934
pii: S0167-8140(22)04244-X
doi: 10.1016/j.radonc.2022.08.023
pii:
doi:

Substances chimiques

Water 059QF0KO0R
Alanine OF5P57N2ZX

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

203-209

Subventions

Organisme : NCI NIH HHS
ID : P01 CA244091
Pays : United States

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Patrik Gonçalves Jorge (PG)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Stavros Melemenidis (S)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Veljko Grilj (V)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Thierry Buchillier (T)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Rakesh Manjappa (R)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Vignesh Viswanathan (V)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Maude Gondré (M)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Marie-Catherine Vozenin (MC)

CHUV - Radiation-oncology Laboratory, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Jean-François Germond (JF)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

François Bochud (F)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Raphaël Moeckli (R)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Charles Limoli (C)

Department of Radiation Oncology, University of California, Irvine, CA 92697, USA.

Lawrie Skinner (L)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Hyunsoo Joshua No (HJ)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Yufan Fred Wu (YF)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Murat Surucu (M)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Amy S Yu (AS)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Brianna Lau (B)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Jinghui Wang (J)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Emil Schüler (E)

Department of Radiation Physics, MD Anderson Cancer Center, Houston, TX 77030, USA.

Karl Bush (K)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Edward E Graves (EE)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Peter G Maxim (PG)

Department of Radiation Oncology, University of California, Irvine, CA 92697, USA.

Billy W Loo (BW)

Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Claude Bailat (C)

Institute of Radiation Physics, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland. Electronic address: Claude.bailat@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH